Amoéba Announces Renewal of Board of Directors to Propel Strategic Growth

Amoéba, the industrial biotechnology firm known for its work in microbiological risk treatment, announced a significant update to its Board of Directors on May 2, 2024. This change introduces new members with deep expertise across the company’s key sectors: biocontrol, health, and cosmetics. This update follows the strategic overhaul initiated in December 2023 under the leadership of Benoit Villers.

The updated Board of Directors includes three newly appointed independent directors and one proposed director to be confirmed at the upcoming Annual General Meeting on June 27. Among the new members are Valerie Lorentz-Poinsot, renowned for her leadership at Laboratoires Boiron, and Patrice Sellès, a veteran in global agricultural biotech. The board aims to support Amoéba's entry into cosmetics and its optimized strategy focusing on high-growth, high-value markets.

Amoéba’s strategic refocus emphasizes accelerated pre-commercial phases for its biocontrol agents in agriculture, alongside scaling up production to meet anticipated market demands. The firm expressed gratitude to former board members, including founder Fabrice Plasson, for their years of service and contributions to the company.